Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 7 of 58, showing 10 Applications out of 576 total, starting on record 61, ending on 70

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

61.

ECCT/25/03/05   Sparkle Study -Site 1402
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. Site 1401: Victoria Biomedical Research Institute (Kisumu county)
2. Site 1402: Ahero Clinical trials Unit (Kisumu county)
3. Site 1403: International Cancer Institute (Uasin Gishu county)
4. Site 1404: Kondele Childrens Hospital (Kisumu county)
5. Site 1405: KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
6. Site 1406: Gertrude’s Children’s Hospital. (Nairobi City county)
 
16-12-2025 View

62.

ECCT/25/03/04   Ndovu RCT
    Investigating the optimal management of dolutegravir resistance: an open-label randomised controlled trial of maintaining dolutegravir or switch to ritonavir-boosted darunavir   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kenyatta National Hospital (KNH) (Nairobi City county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
3. Bomu Hospital (Mombasa county)
 
14-07-2025 View

63.

ECCT/25/03/03   ALIM STUDY
    Evaluating the safety and efficacy of Imatinib in combination with Artemether and Lumefantrine for the treatment of Uncomplicated Malaria: a three-part trial.   
Principal Investigator(s)
1. Dr. QUENTIN AWORI
Site(s) in Kenya
VICTORIA BIOMEDICAL RESEARCH INSTITUTE
 
27-10-2025 View

64.

ECCT/25/03/01   MK-5684_MSD (mCRPC)
     A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)    
Principal Investigator(s)
1. PROF MANSOOR NOORALI SALEH
Site(s) in Kenya
AGA KHAN UNIVERSITY HOSPITAL NAIROBI
 
20-05-2025 View

65.

ECCT/25/02/11   Extended Dosing OCV Trial
    A Phase IV Parallel-Group, Open-Label, Randomized Non-Inferiority Trial Evaluating Immunogenicity of Extended Dosing Intervals for Euvichol-S Oral Cholera Vaccine, Nairobi, Kenya   
Principal Investigator(s)
1. Samuel Kariuki
Site(s) in Kenya
MMM MUKURU HEALTH CENTRE
 
16-07-2025 View

66.

ECCT/25/02/10   PrEP My Way II
    PrEP My Way: A hybrid type 1 clinical effectiveness-implementation trial to promote PrEP persistence among young Kenyan women   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI RCTP
 
17-06-2025 View

67.

ECCT/25/02/09   DASH II Study
    Diagnostic Access to Self-Care & Health Services in Low- and Middle-Income Countries (DASH) – Phase II Study   
Principal Investigator(s)
1. ELIZABETH ANNE BUKUSI
Site(s) in Kenya
Migori County
 
23-05-2025 View

68.

ECCT/25/02/08   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Valentine Chepkorir Sing’oei
Site(s) in Kenya
1. KEMRI –USAMRD-A, Kombewa Clinical Research Centre (Kisumu county)
 
06-03-2025 View

69.

ECCT/25/02/07   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. KEMRI-RCTP (Kisumu county)
 
13-03-2025 View

70.

ECCT/25/02/06   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
 
06-03-2025 View